R&D

Protein identified as new therapeutic anti-viral target for COVID-19

New research identified a novel interaction between the SARS-CoV-2 spike protein and the galectin-3-binding protein (LGALS3BP) which could be a new therapeutic anti-viral target. The research also found the presence of detectable viral RNA in blood in COVID-19 patients is a strong predictor of mortality.

How to obtain immune bovine milk to strengthen the body against COVID-19

Physiologically, milk contains biocomponents that are highly protective against infections. In light of this, the AGR-149-Infectious Diseases group at the University of Cordoba's Department of Animal Health is doing research that focuses on cow's milk as a possible source of COVID-19 control. The results have been published, partially, in the journal Frontiers in Immunology.

New study may help explain low oxygen levels in COVID-19 patients

A new study published in the journal Stem Cell Reports by University of Alberta researchers is shedding light on why many COVID-19 patients, even those not in hospital, are suffering from hypoxia--a potentially dangerous condition in which there is decreased oxygenation in the body's tissues. The study also shows why the anti-inflammatory drug dexamethasone has been an effective treatment for those with the virus.

WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations

WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing. The vaccine is produced by the Beijing-based pharmaceutical company Sinovac.

Africa urgently needs 20 million second doses of COVID-19 vaccine

Africa needs at least 20 million doses of the Oxford-AstraZeneca vaccine in the next six weeks to get second doses to all who received a first dose within the 8 - 12-week interval between doses recommended by the World Health Organization (WHO).

60 million doses of COVID-19 vaccine administered in UK

Health services across the UK have now administered a total of around 60.6 million vaccines since 8 December, including around 37.9 million people with their first dose (72%) and 22.6 million with both doses (43%), ensuring they have the strongest possible protection against COVID-19 from a second dose.

Why are some COVID-19 vaccines working better for men than women?

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine.

If there's one take-home message for the general public about the coronavirus vaccines approved in the U.S., it's that they are remarkably effective.

Research & Development

Protein identified as new therapeutic anti-viral target for COVID-19

How to obtain immune bovine milk to strengthen the body against COVID-19

New study may help explain low oxygen levels in COVID-19 patients

WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations

Africa urgently needs 20 million second doses of COVID-19 vaccine

60 million doses of COVID-19 vaccine administered in UK

Why are some COVID-19 vaccines working better for men than women?

More Pharma News ...